Xian janssen pharmaceutical china and the euro

For Prof Moses Assignment

Company News 12:02PM, 23 September 2015 - Report: J&J had plan to block more FDA restrictions on Tylenol - BioPharma Dive 11:11AM, 23 September 2015 - FDA Was Pressured By J&J Not to Address Tylenol Liver Damage Risk: Report - AboutLawsuits.com 11:10AM, 23 September 2015 - U of Toronto to collaborate with Johnson & Johnson on health start-ups - Technology Transfer Tactics 9:52AM, 23 September 2015 - Nike, Johnson & Johnson, Starbucks, And Others Join Pledge For 100% Renewable Electricity - CleanTechnica 9:00AM, 23 September 2015 - Dishman gets licence from JJ to make TB drug raw material - Money Control 8:19AM, 23 September 2015 - Risperdal Litigation Pioneer Stephen Sheller Featured in "DocuSerial" about Johnson & Johnson, "America's Most Admired Lawbreaker" by Steve Brill - PR Newswire 3:21AM, 23 September 2015 - Dishman Pharma to make TB drug exclusively for JJ - Money Control 11:10PM, 22 September 2015 - Fortune 500 listed companies pledge to use 100% renewable electricity - Blue and Green Tomorrow 3:00PM, 22 September 2015 - Johnson & Johnson: A Gold Standard Dividend Stock - Seeking Alpha 11:03AM, 22 September 2015 - J&J faces Tylenol lobbying allegations in first case to go to trial over med

Johnson & Johnson

09/23/2015 3 Mergent, Inc.

- FiercePharma

Corporate Events Earnings Announcement Data - October 13 2015 : On Oct. 13, 2015, Co. announced its 3rd quarter earnings before market (confirmed). Conference Call Announcements - October 13 2015 : On Oct. 13, 2015, Co. scheduled a conference call at 12:30pm. Conference Call Announcements - July 14 2015 : On July 14, 2015, Co. scheduled a conference call at 12:30pm. Earnings Announcement Data - July 14 2015 : On July 14, 2015, Co. announced its 2nd quarter earnings (confirmed). Earnings Announcement Data - April 14 2015 : On Apr. 14, 2015, Co. announced its 1st quarter earnings before market (confirmed). Earnings Announcement Data - April 14 2015 : On Apr. 14, 2015, Co. announced its 1st quarter earnings before market (confirmed). Conference Call Announcements - April 14 2015 : On Apr. 14, 2015, Co. scheduled a conference call at 12:30pm.

Key Executives Alex Gorsky Age Salary Chairman,Chief Executive Officer 55 1,500,000

Dominic Caruso Age Salary Vice President,Chief Financial Officer 57 878,115

Peter Fasolo Age Salary Vice President 52 534,769

Michael Ullmann Age Salary Vice President,General Counsel 57 591,346

Paulus Stoffels Age Salary Chief Scientific Officer 53 1,075,423

Key Financials (In USD as of 06/28/2015)

Income Statement Revenue 71,882m Net Income 16,106m EPS from Continuing Operations 5.69 EPS - Net Income - Diluted 5.69 Revenue per Share 25.93 Balance Sheet Total Assets 132,036m Total Liabilities 60,905m Shareholders' Equity 71,131m Total Assets per Share 47.68 Net Assets per Share 25.69

Johnson & Johnson

09/23/2015 4 Mergent, Inc.

Cash Flows Cash from Operations 17,091m Cash from Investing -7,530m Cash from Financing -12,065m Capital Expenditures 3,555m Cash Flow per Share 6.08

Financial Highlights

Financial Highlights as of 12/28/2014 in USD Income Statement (In Thousands) Total Revenue 74,331,000 EBITDA 24,927,000 Operating Income 20,959,000 Net Income 16,323,000 Revenue per Share 26.48 EPS from Continuing Operations 5.70 EPS - Net Income - Diluted 5.70 Share Outstanding 2,783,223 Weighted Average Shares Outstanding - Basic 2,815,200 Weighted Average Shares Outstanding - Diluted 2,863,900 Earnings per Share - Basic 5.80 Balance Sheet (In Thousands) Total Assets 131,119,000 Current Assets 59,311,000 Total Liabilities 61,367,000 Long Term Debt 15,122,000 Stockholders' Equity 69,752,000 Total Assets per Share 47.11 Current Liabilities 25,085,000 Net Assets per Share 25.06 Cash Flow Statement (In Thousands) Cash from Operations 18,471,000 Cash from Investing (12,305,000) Cash from Financing (12,260,000) Capital Expenditures 3,714,000 Cash Flow per Share 6.45 Cash & Cash Equivalents, Beginning of Year 20,927,000 Cash & Cash Equivalents, End of Year 14,523,000 Stock Price and Valuation (Data as of 09/22/2015) Market Cap(mil) 258,191 Share Outstanding(000's) 2,769,106 PE Ratio 16.3866 Dividend Per Share(TTM) 2.9 Earning Per Share(TTM) 5.78 Last Closing Price 93.24 Previous Trading Day Range 91.88 - 93.44 52 Week Range 90.73 - 109.07 7 Day Average Closing Price 93.94 30 Day Average Closing Price 93.44

Johnson & Johnson

09/23/2015 5 Mergent, Inc.

200 Day Average Closing Price 98.98 Beta 0.55 High Price Last 3 Mos. 101.11 Low Price Last 3 Mos. 90.73 Avg Daily Volume Last 3 Mos. 8,391,457.25

Management Effectiveness Revenue per Employee 589,211 Net Income per Employee 129,390 ROA % (Net) 12.41 ROE % (Net) 22.76 ROI % (Operating) 23.26 Profitability Ratios Gross Margin 69.40 Operating Margin 28.20 EBITDA Margin % 33.54 Calculated Tax Rate % 20.62 Profit Margin (TTM) 21.96 Valuation Ratios Price/Earnings (TTM) 18.06 Price/Book (TTM) 4.19 Price/Cash Flow(TTM) 15.97 Asset Management Total Asset Turnover 0.57 Receivables Turnover 6.57 Inventory Turnover 2.83 Property Plant & Equip Turnover 4.54 Cash & Equivalents Turnover 4.21 Debt Management Interest Coverage 44.98 Long Term Debt/Equity 0.22 Long Term Debt as % of Invested Capital 17.08 Total Debt/Equity 0.27 Accounts Payable Turnover 10.73 Accrued Expenses Turnover 5.25 Liquidity Indicators Quick Ratio 1.76 Current Ratio 2.36 Net Current Assets as % of Total Assets 26.10 Free Cash Flow per Share 5.26 Revenue to Assets 0.57 Consensus Estimates 2015Ae 2015Q3e 2015Q4e Earnings Per Share 6.16 1.46 1.44 Revenue 70,714.15 17,502.00 18,012.96 EBITDA 23,750.63 5,691.94 5,272.88

Property

Co. maintains its principal executive offices in New Brunswick, NJ.

Co.'s subsidiaries operate 134 manufacturing facilities occupying approx. 21,500,000 sq. ft. of floor space.

Johnson & Johnson

09/23/2015 6 Mergent, Inc.

The following table sets forth information regarding the manufacturing facilities used by the industry segments of Co.'s business as of Dec. 28, 2014:

Segment [1]Sq. Ft. Consumer 7,213 Pharmaceutical 7,404 Medical Devices 6,850 Total 21,467

[1]In thousands

The following table sets forth information regarding the locations of Co.'s manufacturing facilities by geographic areas as of Dec. 28, 2014:

Geographic Area [1]Sq. Ft. U.S. (42) 5,892 Europe (41) 7,673 Western Hemisphere, excluding U.S. (15) 3,005 Africa, Asia and Pacific (36) 4,897 Total 21,467

[1]In thousands

In addition, Co. and its subsidiaries maintain several office and warehouse facilities throughout the world.

Principal Executive Offices One Johnson & Johnson Plaza New Brunswick, NJ 08933 United States

Subsidiaries

SUBSIDIARY NAME PERCENT OWNED COUNTRY Subsidiaries Subsidiaries Acclarent, Inc. 100% United States ALZA Corporation 100% United States Animas Corporation 100% United States Aragon Pharmaceuticals, Inc. 100% United States Biosense Webster, Inc. 100% United States CNA Development LLC 100% United States Codman & Shurtleff, Inc. 100% United States Cordis Corporation 100% United States Cordis International Corporation 100% United States Cordis LLC 100% United States DePuy Mitek Holding Corporation 100% United States DePuy Mitek, LLC 100% United States DePuy Orthopaedics, Inc. 100% United States DePuy Products, Inc. 100% United States

Johnson & Johnson

09/23/2015 7 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY DePuy Spine, LLC 100% United States DePuy Synthes Sales, Inc. 100% United States DePuy Synthes, Inc. 100% United States Diabetes Diagnostics, Inc. 100% United States Ethicon Endo-Surgery, Inc. 100% United States Ethicon Endo-Surgery, LLC 100% United States Ethicon LLC 100% United States Ethicon US, LLC 100% United States Ethicon, Inc. 100% United States Flexible Stenting Solutions, Inc. 100% United States J&J Holdings (Nevada), Inc. 100% United States Janssen Alzheimer Immunotherapy 100% United States Research & Development, LLC Janssen Biotech, Inc. 100% United States Janssen Global Services, LLC 100% United States Janssen Oncology, Inc. 100% United States Janssen Ortho LLC 100% United States Janssen Pharmaceuticals, Inc. 100% United States Janssen Products, LP 100% United States Janssen Research & 100% United States Development, LLC Janssen Scientific Affairs, LLC 100% United States Janssen Supply Group, LLC 100% United States Janssen-Cilag Manufacturing, LLC 100% United States JJHC, LLC 100% United States JNJ International Investment LLC 100% United States Johnson & Johnson (Middle 100% United States East) Inc. Johnson & Johnson Consumer 100% United States Companies, Inc. Johnson & Johnson Development 100% United States Corporation Johnson & Johnson Finance 100% United States Corporation Johnson & Johnson Health Care 100% United States Systems Inc. Johnson & Johnson International 100% United States Johnson & Johnson Japan Inc. 100% United States Johnson & Johnson Sales and 100% United States Logistics Company, LLC Johnson & Johnson Services, 100% United States Inc. Johnson & Johnson Urban 100% United States Renewal Associates Johnson & Johnson Vision Care, 100% United States Inc. JOM Pharmaceutical Services, Inc. 100% United States LifeScan LLC 100% United States LifeScan Products, LLC 100% United States LifeScan, Inc. 100% United States

Johnson & Johnson

09/23/2015 8 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY McNeil Consumer Pharmaceuticals Co. 100% United States McNeil Healthcare LLC 100% United States McNeil LA LLC 100% United States McNEIL MMP, LLC 100% United States McNeil Nutritionals, LLC 100% United States McNEIL-PPC, Inc. 100% United States Mentor Texas L.P. 100% United States Mentor Worldwide LLC 100% United States Micro Typing Systems, Inc. 100% United States Micrus Endovascular LLC 100% United States Middlesex Assurance Company Limited 100% United States Neutrogena Corporation 100% United States Noramco, Inc. 100% United States OMJ Pharmaceuticals, Inc. 100% United States Omrix Biopharmaceuticals, Inc. 100% United States Ortho Biologics LLC 100% United States Ortho-Clinical Diagnostics, Inc. 100% United States Rutan Realty LLC 100% United States Scios LLC 100% United States SterilMed, Inc. 100% United States Synthes USA Products, LLC 100% United States Synthes USA, LLC 100% United States Synthes, Inc. 100% United States The Anspach Effort, LLC 100% United States Wellness & Prevention, Inc. 100% United States Almaco Holding AG 100% Switzerland Apsis 100% France Apsis Germany GmbH 100% Germany Beijing Dabao Cosmetics Co., Ltd. 100% China (Peoples

Rep. Of) Berna Biotech Korea Corporation 100% Korea (South) Berna Rhein B.V. 100% Netherlands Biosense Webster (Israel) Ltd. 100% Israel Cilag Advanced Technologies GmbH 100% Switzerland Cilag AG 100% Switzerland Cilag GmbH International 100% Switzerland Cilag Holding AG 100% Switzerland Cilag Pharmaceuticals GmbH 100% Switzerland Cilag Products GmbH 100% Switzerland Cordis de Mexico, S.A. de C.V. 100% Mexico Cordis Europa NV 100% Netherlands Corimmun GmbH 100% Germany Crucell Holland B.V. 100% Netherlands Crucell N.V. 100% Netherlands Crucell Sweden AB 100% Sweden Crucell Switzerland AG 100% Switzerland DePuy (Ireland) 100% Ireland DePuy France 100% France DePuy International (Holdings) 100% United Kingdom Limited

Johnson & Johnson

09/23/2015 9 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY DePuy International Limited 100% United Kingdom DePuy Medical Private Limited 100% India DePuy Mitek Sarl 100% Switzerland DePuy Synthes Apollo Limited 100% Ireland DePuy Synthes Eos Limited 100% Ireland DePuy Synthes Gorgan Limited 100% Ireland DePuy Synthes Jason Limited 100% Ireland DePuy Synthes Leto S.A.R.L. 100% Ireland DePuy UK Holdings Limited 100% United Kingdom EES Holdings de Mexico, S. de R.L. 100% Mexico de C.V. Ethicon 100% France Ethicon Ireland 100% Ireland Ethicon PR Holdings 100% Ireland Ethicon Women's Health & 100% Switzerland Urology Sarl Ethnor Farmaceutica, S.A. 100% Venezuela FMS Future Medical System SA 100% Switzerland GMED Healthcare BVBA 100% Belgium J.C. General Services CVBA 100% Belgium Janssen Alzheimer Immunotherapy 100% Ireland Janssen Alzheimer Immunotherapy 100% Ireland (Holding) Limited Janssen Biologics (Ireland) 100% Ireland Janssen Biologics B.V. 100% Netherlands Janssen Cilag Farmaceutica S.A. 100% Argentina Janssen de Mexico S. de R.L. de 100% Mexico C.V. Janssen Inc. 100% Canada Janssen Infectious 100% Belgium Diseases-Diagnostics BVBA Janssen Korea Ltd. 100% Korea (South) Janssen Pharmaceutica NV 100% Belgium Janssen Pharmaceutical 100% Ireland Janssen Pharmaceutical Holdings 100% Ireland Janssen Pharmaceutical K.K. 100% Japan Janssen R&D Ireland 100% Ireland Janssen-Cilag 100% France Janssen-Cilag AB 100% Sweden Janssen-Cilag AG 100% Switzerland Janssen-Cilag B.V. 100% Netherlands Janssen-Cilag Farmaceutica Ltda. 100% Brazil Janssen-Cilag Farmaceutica, Lda. 100% Portugal Janssen-Cilag GmbH 100% Germany Janssen Cilag Limited 100% Thailand Janssen-Cilag Limited 100% United Kingdom Janssen-Cilag NV 100% Belgium Janssen-Cilag OY 100% Finland Janssen-Cilag Pharma GmbH 100% Austria Janssen-Cilag Pharmaceutical 100% Greece

Johnson & Johnson

09/23/2015 10 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY S.A.C.I. Janssen-Cilag Pty Ltd 100% Australia Janssen-Cilag S.p.A. 100% Italy Janssen-Cilag, C.A. 100% Venezuela Janssen-Cilag, S.A. 100% Spain Janssen-Cilag, S.A. de C.V. 100% Mexico J-C Health Care Ltd. 100% Israel JJC Acquisition Company B.V. 100% Netherlands Johnson & Johnson (China) 100% China (Peoples Investment Ltd. Rep. Of) Johnson & Johnson (China) Ltd. 100% China (Peoples

Rep. Of) Johnson & Johnson (Hong Kong) 100% Hong Kong Limited Johnson & Johnson (Ireland) 100% Ireland Limited Johnson & Johnson (New 100% New Zealand Zealand) Limited Johnson & Johnson 100% Philippines (Philippines), Inc. Johnson & Johnson 100% South Africa (Proprietary) Limited Johnson & Johnson (Thailand) 100% Thailand Ltd. Johnson & Johnson AB 100% Sweden Johnson & Johnson AG 100% Switzerland Johnson & Johnson Consumer 100% Thailand (Thailand) Limited Johnson & Johnson Consumer B.V. 100% Netherlands Johnson & Johnson Consumer 100% France Holdings France Johnson & Johnson Consumer 100% United Kingdom Services EAME Ltd. Johnson & Johnson de Argentina 100% Argentina S.A.C. e. I. Johnson & Johnson de Chile S.A. 100% Chile Johnson & Johnson de Colombia 100% Colombia S.A. Johnson & Johnson de Mexico, 100% Mexico S.A. de C.V. Johnson & Johnson de 100% Venezuela Venezuela, S.A. Johnson & Johnson del Ecuador 100% Ecuador S.A. Johnson & Johnson del Peru S.A. 100% Peru Johnson & Johnson do Brasil 100% Brazil Industria E Comercio de Produtos Para Saude Ltda. Johnson & Johnson European 100% Ireland Treasury Company

Johnson & Johnson

09/23/2015 11 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY Johnson & Johnson Finance 100% United Kingdom Limited Johnson & Johnson Financial 100% Germany Services GmbH Johnson & Johnson Gesellschaft 100% Austria m.b.H. Johnson & Johnson GmbH 100% Germany Johnson & Johnson Group 100% Germany Holdings GmbH Johnson & Johnson Hellas 100% Greece Commercial and Industrial S.A. Johnson & Johnson Holding GmbH 100% Germany Johnson & Johnson Inc. 100% Canada Johnson & Johnson Industrial 100% Brazil Ltda. Johnson & Johnson 100% Ireland International Financial Services Company Johnson & Johnson K.K. 100% Japan Johnson & Johnson Kft. 100% Hungary Johnson & Johnson Korea 100% Korea (South) Selling & Distribution Limited Liability Company Johnson & Johnson Korea, Ltd. 100% Korea (South) Johnson & Johnson Limitada 100% Portugal Johnson & Johnson Limited 100% India Johnson & Johnson Limited 100% United Kingdom Johnson & Johnson LLC 100% Russia Johnson & Johnson Luxembourg 100% Luxembourg Finance Company Sarl Johnson & Johnson Management 100% United Kingdom Limited Johnson & Johnson Medical 100% China (Peoples (China) Ltd. Rep. Of) Johnson & Johnson Medical 100% South Africa (Pty) Limited Johnson & Johnson Medical 100% China (Peoples (Shanghai) Ltd. Rep. Of) Johnson & Johnson Medical 100% China (Peoples (Suzhou) Ltd. Rep. Of) Johnson & Johnson Medical B.V. 100% Netherlands Johnson & Johnson Medical GmbH 100% Germany Johnson & Johnson Medical 100% Korea (South) Korea Limited Johnson & Johnson Medical 100% United Kingdom Limited Johnson & Johnson Medical 100% Mexico Mexico, S.A. de C.V. Johnson & Johnson Medical NV 100% Belgium Johnson & Johnson Medical 100% Austria

Johnson & Johnson

09/23/2015 12 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY Products GmbH Johnson & Johnson Medical Pty 100% Australia Ltd Johnson & Johnson Medical S.A. 100% Argentina Johnson & Johnson Medical 100% Italy S.p.A. Johnson & Johnson Medical, 100% Venezuela S.C.S. Johnson & Johnson Middle East 100% United Arab FZ-LLC Emirates Johnson & Johnson Pacific Pty. 100% Australia Limited Johnson & Johnson Poland Sp. z 100% Poland o.o. Johnson & Johnson Pte. Ltd. 100% Singapore Johnson & Johnson Pty. Limited 100% Australia Johnson & Johnson S.p.A. 100% Italy Johnson & Johnson SDN. BHD. 100% Malaysia Johnson & Johnson Sihhi 100% Turkey Malzeme Sanayi Ve Ticaret Limited Sirketi Johnson & Johnson Swiss 100% United Kingdom Finance Company Limited Johnson & Johnson Taiwan Ltd. 100% Taiwan Johnson & Johnson Vision Care 100% Ireland (Ireland) Johnson & Johnson, prodaja 100% Slovenia medicinskih in farmacevtskih izdelkov, d.o.o. Johnson & Johnson, S.A. 100% Spain Johnson & Johnson, S.A. de C.V. 100% Mexico Johnson & Johnson, s.r.o. 100% Czech Republic Latam International Investment 100% Ireland Company Latam Properties Holdings 100% Ireland LifeScan Scotland Limited 100% United Kingdom McNeil AB 100% Sweden McNeil GmbH & Co. oHG 100% Germany McNeil Healthcare (UK) Limited 100% United Kingdom McNeil Manufacturing Pty Ltd 100% Australia McNeil Products Limited 100% United Kingdom McNeil Sweden AB 100% Sweden Medos International Sarl 100% Switzerland Medos Sarl 100% Switzerland Mentor Medical Systems B.V. 100% Netherlands Mentor Medical Systems C.V. 100% Netherlands OBTECH Medical Sarl 100% Switzerland OMJ Ireland 100% Ireland OMJ PR Holdings 100% Ireland Omrix Biopharmaceuticals Ltd. 100% Israel

Johnson & Johnson

09/23/2015 13 Mergent, Inc.

SUBSIDIARY NAME PERCENT OWNED COUNTRY Ortho-Clinical Diagnostics 100% France Ortho-Clinical Diagnostics 100% United Kingdom Ortho-Clinical Diagnostics GmbH 100% Germany Ortho-Clinical Diagnostics K.K. 100% Japan Ortho-Clinical Diagnostics NV 100% Belgium P.T. Johnson & Johnson 100% Indonesia Indonesia Shanghai Elsker Mother & Baby 100% China (Peoples Co., Ltd Rep. Of) Shanghai Johnson & Johnson 100% China (Peoples Pharmaceuticals, Ltd. Rep. Of) Synthes (Canada) Ltd. 100% Canada Synthes (Shanghai) Medical Trading 100% China (Peoples Co., Ltd. Rep. Of) Synthes (Suzhou) Medical Co., Ltd. 100% China (Peoples

Rep. Of) Synthes Australia Pty Ltd 100% Australia Synthes Colombia S.A.S. 100% Colombia Synthes Finanz AG 100% Switzerland SYNTHES GmbH 100% Germany Synthes GmbH 100% Switzerland Synthes Holding AG 100% Switzerland Synthes Industria e Comercio Ltda. 100% Brazil Synthes Limited 100% United Kingdom Synthes Lux Finance S.ar.l. 100% Luxembourg Synthes Lux Holding S.ar.l. 100% Luxembourg Synthes Luxembourg, S.ar.l. 100% Luxembourg Synthes Medical Private Limited 100% India Synthes Produktions GmbH 100% Switzerland Synthes Tuttlingen GmbH 100% Germany Synthes-Stratec S.A. 100% Spain Tasmanian Alkaloids Pty. Ltd. 100% Australia Tibotec-Virco Comm. VA 100% Belgium Turnbuckle Investment Company 100% Ireland Vania Expansion 100% France Xian-Janssen Pharmaceutical Ltd. 100% China (Peoples

Rep. Of)

Long Term Debt Dec. 28, 2014, $15,129,000,000 (including current portion of $7,000,000) comprised of:

-- 01 -- $898,000,000 2.15% notes, due 2016.

-- 02 -- $800,000,000 long-term debt, bearing interest at three month London Interbank Offered Rate (LIBOR) plus 0.07% FRN (effective interest rate was 0.31% at Dec. 28, 2014), due 2016.

-- 03 -- $398,000,000 0.70% notes, due 2016.

-- 04 -- $1,000,000,000 5.55% debentures, due 2017.

Johnson & Johnson

09/23/2015 14 Mergent, Inc.

-- 05 -- $697,000,000 1.125% notes, due 2017.

-- 06 -- $898,000,000 5.15% debentures, due 2018.

-- 07 -- $597,000,000 1.65% notes, due 2018.

-- 08 -- $1,216,000,000 4.75% notes, due 2019.

-- 09 -- $497,000,000 1.875% notes, due 2019.

-- 10 -- $158,000,000 3% zero coupon convertible subordinated debentures, due 2020.

-- 11 -- $543,000,000 2.95% debentures, due 2020.

-- 12 -- $446,000,000 3.55% notes, due 2021.

-- 13 -- $349,000,000 2.45% notes, due 2021.

-- 14 -- $250,000,000 6.73% debentures, due 2023.

-- 15 -- $812,000,000 3.375% notes, due 2023.

-- 16 -- $772,000,000 5.50% notes, due 2024.

-- 17 -- $297,000,000 6.95% notes, due 2029.

-- 18 -- $500,000,000 4.95% debentures, due 2033.

-- 19 -- $865,000,000 4.375% notes, due 2033.

-- 20 -- $995,000,000 5.95% notes, due 2037.

-- 21 -- $700,000,000 5.85% debentures, due 2038.

-- 22 -- $539,000,000 4.50% debentures, due 2040.

-- 23 -- $298,000,000 4.85% notes, due 2041.

-- 24 -- $499,000,000 4.50% notes, due 2043.

-- 25 -- $105,000,000 other long-term debt.

Line of Credit: Co. has access to substantial sources of funds at several banks worldwide. In Sept. 2014, Co. secured a 364-day Credit Facility. Total credit available to Co. approximates $10,000,000,000, which expires on Sept. 17, 2015. Interest charged on borrowings under the credit line agreements is based on either bids provided by banks, the prime rate or LIBOR, plus applicable margins.

For details see below.

Expanded Long Term Debt CUSIP Issuer Name Issue Description Ticker

Johnson & Johnson

09/23/2015 15 Mergent, Inc.

CUSIP Issuer Name Issue Description Ticker 478160AB0 JOHNSON & JOHNSON NT JNJ 478160AA2 JOHNSON & JOHNSON NT JNJ 478160AC8 JOHNSON & JOHNSON NT JNJ 478160AD6 JOHNSON & JOHNSON NT JNJ 218525AA1 CORDIS CORPORATION SUB DEB JNJ 152342AB7 CENTOCOR INCORPORATED SUB DEB CONV JNJ 152342AA9 CENTOCOR INCORPORATED SUB NT CONV JNJ 4781609A0 JOHNSON & JOHNSON NT REG S JNJ 478160AE4 JOHNSON & JOHNSON NT JNJ 421969AA4 HEARTPORT INCORPORATED SUB NT CONV RULE 144A JNJ 421969AC0 HEARTPORT INCORPORATED SUB NT CONV JNJ 152342AE1 CENTOCOR INCORPORATED SUB DEB CONV JNJ 022615AD0 ALZA CORPORATION SUB DEB CONV JNJ 808905AB9 SCIOS INCORPORATED SUB NT CONV JNJ 808905AA1 SCIOS INCORPORATED SUB NT CONV RULE 144A JNJ 478160AK0 JOHNSON & JOHNSON DEB JNJ 022615AB4 ALZA CORPORATION LIQUID YIELD OPT NT JNJ

(LYONS) 478160AP9 JOHNSON & JOHNSON GLOBAL NT JNJ 478160AM6 JOHNSON & JOHNSON GLOBAL DEB JNJ 022615AC2 ALZA CORPORATION SUB NT ZERO CPN CONV JNJ

(LYON) 478160AQ7 JOHNSON & JOHNSON GLOBAL NT JNJ 478160AS3 JOHNSON & JOHNSON EUR$ GLOBAL NT JNJ 02261WAB5 ALZA CORPORATION SUB DEB ZERO CPN CONV JNJ 02261WAA7 ALZA CORPORATION SUB DEB ZERO CPN CONV JNJ

RULE 144A 478160AF1 JOHNSON & JOHNSON DEB JNJ 478160AG9 JOHNSON & JOHNSON DEB JNJ 478160AR5 JOHNSON & JOHNSON GBP$ GLOBAL NT JNJ 478160AJ3 JOHNSON & JOHNSON DEB JNJ 478160AL8 JOHNSON & JOHNSON GLOBAL DEB JNJ 478160AN4 JOHNSON & JOHNSON GLOBAL NT JNJ

CUSIP Coupon Maturity Active 478160AB0 8.87510/15/1990 No 478160AA2 9.12509/15/1992 No 478160AC8 8.508/15/1995 No 478160AD6 809/01/1998 No 218525AA1 12.2506/15/1999 No 152342AB7 6.7502/01/2001 No 152342AA9 7.2502/01/2001 No 4781609A0 607/19/2001 No 478160AE4 7.37506/29/2002 No 421969AA4 7.2505/01/2004 No 421969AC0 7.2505/01/2004 No 152342AE1 4.7502/15/2005 No 022615AD0 505/01/2006 No 808905AB9 5.508/15/2009 No 808905AA1 5.508/15/2009 No

Johnson & Johnson

09/23/2015 16 Mergent, Inc.

CUSIP Coupon Maturity Active 478160AK0 6.62509/01/2009 No 022615AB4 012/21/2010 No

478160AP9 5.1508/15/2012 No 478160AM6 3.805/15/2013 No 022615AC2 007/14/2014 No

478160AQ7 5.5508/15/2017 Yes 478160AS3 -11/06/2019 Yes 02261WAB5 007/28/2020 Yes 02261WAA7 007/28/2020 No

478160AF1 6.7311/15/2023 Yes 478160AG9 8.7211/01/2024 No 478160AR5 -11/06/2024 Yes 478160AJ3 6.9509/01/2029 Yes 478160AL8 4.9505/15/2033 Yes 478160AN4 5.9508/15/2037 Yes

Capital Structure Abbreviation Description Structure Type Exchange Ticker Market Cap Com Com Common NYS JNJ 258,191,443,440

Business Segments

Business Analysis Revenues

Report Date 12/28/2014 12/29/2013 12/30/2012 01/01/2012 Currency USD USD USD USD Scale Millions Millions Millions Millions Consumer 14,496 14,697 14,447 14,883 Pharmaceutical 32,313 28,125 25,351 24,368 Medical Devices & Diagnostics 27,522 28,490 27,426 25,779 Total 74,331 71,312 67,224 65,030

Operating Income Report Date 01/02/2011 12/28/2014 12/29/2013 12/30/2012 Currency USD USD USD USD Scale Millions Millions Millions Millions Consumer 14,590 1,941 1,973 1,693 Pharmaceutical 22,396 11,696 9,178 6,075 Medical Devices & Diagnostics 24,601 7,953 5,261 7,187 Total 61,587 21,590 16,412 14,955

Report Date 01/01/2012 01/02/2011 Currency USD USD

Johnson & Johnson

09/23/2015 17 Mergent, Inc.

Report Date 01/01/2012 01/02/2011 Currency USD USD Scale Millions Millions Consumer 2,096 2,342 Pharmaceutical 6,406 7,086 Medical Devices & Diagnostics 5,263 8,272 Total 13,765 17,700

Geographic Analysis

Revenues Report Date 12/28/2014 Currency USD Scale Millions United States 34,782 Europe 18,947 Western Hemisphere excluding U.S. 7,160 Asia-Pacific, Africa 13,442 Total 74,331

Report Date 12/29/2013 Currency USD Scale Millions United States 31,910 Europe 18,599 Western Hemisphere excluding U.S. 7,421 Asia-Pacific, Africa 13,382 Total 71,312

Johnson & Johnson

09/23/2015 18 Mergent, Inc.

Report Date 12/30/2012 Currency USD Scale Millions United States 29,830 Europe 16,945 Western Hemisphere excluding U.S. 7,207 Asia-Pacific, Africa 13,242 Total 67,224

Report Date 01/01/2012 Currency USD Scale Millions United States 28,908 Europe 17,129 Western Hemisphere excluding U.S. 6,418 Asia-Pacific, Africa 12,575 Total 65,030

Johnson & Johnson

09/23/2015 19 Mergent, Inc.

Report Date 01/02/2011 Currency USD Scale Millions United States 29,450 Europe 15,510 Western Hemisphere excluding U.S. 5,550 Asia-Pacific, Africa 11,077 Total 61,587